Physician profile
Tim P Gurtch
NPI 1881694776
$1,631.91
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $577 · 2021: $318 · 2022: $279 · 2023: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $379.22 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $222.13 | 2020-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $217.37 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $206.42 | 2019-2020 | |
| Astellas Pharma US INC | $128.06 | 2019-2020 | |
| Nevro Corp. | $82.18 | 2022-2023 | Senza |
| Glaxosmithkline, LLC. | $66.92 | 2021-2022 | |
| Abbvie INC. | $59.73 | 2021-2022 | |
| Allergan, INC. | $49.62 | 2020 | |
| Pfizer INC. | $48.80 | 2021 | |
| Eisai INC. | $35.67 | 2020 | |
| Boston Scientific Corporation | $31.08 | 2020 | |
| Idorsia Pharmaceuticals US INC | $28.77 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $27.64 | 2023 | Rexulti |
| Amarin Pharma, INC. | $15.86 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $12.64 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.79 | 2020 | |
| Stimwave Technologies Incorporated | $8.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tim Gurtch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.